Multiple myeloma with intracranial extension and bilateral renal infiltration: A case report and review of the literature

MIN-JUAN ZHANG1, GUO-HONG SU1, JIE SHEN1, FENG-HAI LIU2, YAN-FENG XU2, XIAO-LING ZHANG3, QING WANG1, RUI-HUAN WANG1, CHUN-YAN LIU1 and YU-LEI ZHAO1

1Second Department of Haematology; Departments of 2Radiology and 3Pathology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China

Received September 22, 2014; Accepted July 7, 2015

DOI: 10.3892/ol.2015.3567

Abstract. Multiple myeloma (MM) is a rare hematological malignancy, characterized by uncontrolled proliferation of plasma cells in the bone marrow. MM is usually confined to the bone marrow, however, it may occasionally infiltrate other tissues, which is known as extramedullary plasmacytoma (EMP). The majority of EMPs involve the head and neck region, although different anatomical sites, including the gastrointestinal tract, central nervous system, thyroid gland and breast may also be affected. The simultaneous presentation of EMP in the kidney and head is rare, presenting diagnostic challenges due to its unusual location and non-specific or absent symptoms. To the best of our knowledge, no case of extramedullary plasmacytoma presenting with simultaneous renal and intracranial infiltration has been reported in the literature thus far. However, the present study reports a case of primary renal and intracranial extramedullary plasmacytoma in a 76-year-old male patient. The patient presented with a swelling over the right side of the forehead, which had slowly increased in size prior to hospital admission. The swelling was associated with dizziness and weakness, without bone pain. Contrast magnetic resonance imaging suggested an osteolytic skull lesion with intracranial extension. Abdominal enhanced computed tomography scanning revealed a large tumor mass extending around and into the kidneys. Immunohistochemical examination of the renal tumor biopsy, and blood and serum samples, as well as immunoelectrophoresis of serum proteins, resulted in a diagnosis of EMP being proposed. Therefore, the patient was administered with two cycles of cyclophosphamide and thalidomide in combination with dexamethasone. Follow-up imaging performed 4 months later revealed almost complete disappearance of the intracranial tumor mass and renal infiltration. The current study also presented a review of the literature. This study revealed that EMPs may co-exist with MM or present as the main symptom of MM. The diagnosis of an EMP is complex and requires radiological, hematological, biochemical and histological investigation. At present, no guidelines for EMP treatment have been established and thus, treatment options include surgery, chemotherapy and radiotherapy, either alone or in combination. We hypothesize that combined treatment may provide the best patient outcome.

Introduction

Multiple myeloma (MM), or myelomatosis, is a rare type of hematological malignancy that comprises ~10% of all hematological malignancies. It is a neoplastic proliferation characterized by the uncontrolled proliferation of plasma cells in the bone marrow that leads to bone osteolytic destruction, anemia, recurrent infections and renal impairment. The incidence of MM is ~3-4 per 100,000 individuals (1). Common presenting features of MM include bone pain and bone fractures, anemia, increased susceptibility to infections, hypercalcemia, neurological manifestations, hyperviscosity syndrome and renal failure (1,2).

Although MM is usually confined to the bone marrow, it may occasionally infiltrate into other tissues (3,4), and this is known as extramedullary plasmacytoma (EMP). To the best of our knowledge, there are no recommended guidelines for the treatment of EMP. Treatment options include surgery, chemotherapy and radiotherapy, either alone or combination (5). Local radiotherapy is the preferred therapeutic modality for EMP owing to its documented radiosensitivity (6). However, previous studies indicated that a combination treatment may provide the best results (7). The majority of EMPs involve the head and neck regions (8), although different anatomical sites, including the gastrointestinal tract, central nervous system, thyroid gland and breast may also be affected (7). However, it is rare that EMPs present initially with simultaneous intracranial and renal infiltration.

The current study reports a case of primary intracranial and renal plasmacytoma in a 76-year-old male patient. Written informed consent was obtained from the patient’s family and ethical approval was obtained from the committee of Cangzhou Central Hospital (Cangzhou, China).

Correspondence to: Miss. Min-Juan Zhang, Second Department of Haematology, Cangzhou Central Hospital, 201 Xinhua Road, Cangzhou, Hebei 061001, P.R. China

E-mail: zhmj1981@126.com

Key words: multiple myeloma, extramedullary plasmacytoma, intracranial extension, renal infiltration, chemotherapy
Case report

The patient presented to the Cangzhou Central Hospital in March 2014, complaining of swelling over the right side of the forehead, which had been slowly progressing during the 3 months prior to the date of admission, and was associated with dizziness and weakness. The patient did not present bone pain or a tendency for abnormal bleeding, and physical examination excluded lymphadenopathy and organomegally. A tense globular swelling of 5.0-6.5 cm in size was observed over the right frontal area, adhered to the underlying skull and skin. Contrast magnetic resonance imaging (MRI) suggested an osteolytic skull lesion with intracranial extension (Fig. 1A). Abdominal enhanced computed tomography (CT) scanning revealed a large tumor mass extending around and into the kidneys (Fig. 2A). Thus, a right renal biopsy was performed, and histopathological analysis of the tumor sample confirmed it to be plasmacytoma. Immunohistochemical staining was performed using cluster of differentiation (CD)38 and CD138 antibodies purchased from Beijing Xiya Jinqiao Biological Technology Co., Ltd. (Beijing, China). All stains were completed using a BenchMark machine (serial no. 815132; Ventana Medical Systems, Inc., Tucson, AZ, USA) and images were captured with an Olympus BX41 microscope (Olympus, Tokyo, Japan) and Image-Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA). Immunohistochemistry indicated that the tumor cells were positive for CD38 and CD138 (Fig. 3). The blood count demonstrated a hemoglobin concentration of 108 g/l, a white cell count of 6.07 x 10^9 cells/l with no abnormal cells and a platelet count of 143 x 10^9 cells/l. The levels of serum creatinine, calcium and phosphorus were within the normal range (NR). The erythrosedimentation rate was 113 mm/h, and the level of serum β2 microglobulin was 4,499 µmol/l (NR, 0.9-2.7 µmol/l). The total serum protein concentration was 83 g/l (NR, 60-83 g/l), and the levels of immunoglobulin (Ig)G, A and M were 39.25, 3.01 and 0.56 g/l, respectively (NR, 7.0-16.0, 0.7-4.0 and 0.4-2.3 g/l, respectively). Immunoelectrophoresis of serum proteins indicated the presence of an IgG paraprotein, and urine was positive for

![Figure 1. (A) MRI scan identified a tumor located in the right frontal part of the skull with intracranial expansion. (B) MRI scan performed following treatment with chemotherapy demonstrating that the tumor mass had practically disappeared. MRI, magnetic resonance imaging.](image1)

![Figure 2. (A) Enhanced CT scans captured upon presentation revealed that the tumor mass infiltrated bilateral kidneys. (B) CT scans performed following treatment with chemotherapy demonstrated that the tumor masses had disappeared completely. CT, computed tomography.](image2)
The patient's age

4% of all metastatic spread of MM, is rare, occurring in 1% of all the

primary plasma cell tumors (3). In patients with a diagnosis

intracranial extramedullary plasmacytomas account for

occasionally occurring as isolated tumors (11,12). Intracra-

the main symptom, developing during the course of MM, or

infiltration (10). EMPs may coexist with MM, presenting as

controlled plasma cell proliferation and monoclonal plasmacytic

EMP is a rare malignant neoplasm that develops due to uncon-

Discussion

Figure 3. Immunohistochemical analysis of the infiltrate indicated strongly

positive staining for (A) CD38 (magnification, x40) and (B) CD138 (magnifi-

cation, x100). CD, cluster of differentiation.

Bence-Jones (monoclonal) protein, indicating a diagnosis of

MM (9). Bone marrow aspiration revealed 4% restriction of

plasma cells, and whole body bone emission CT demonstrated

multiple abnormal distribution of tracer concentration. Conse-

quently, a diagnosis of MM was established.

The patient and his relatives refused further examination,
surgical operation and radiotherapy, due to the patient’s age

and body condition. Therefore, the patient was subjected to

chemotherapy, and was administered 2 cycles of cyclophos-

phamide and thalidomide in combination with dexamethasone.

Follow-up imaging 4 months later revealed nearly complete

disappearance of the intracranial tumor mass (Fig. 1B) and renal infiltration (Fig. 2B). The clinical condition also

improved, and the patient experienced a complete recovery.

EMP is a rare malignant neoplasm that develops due to uncon-

trolled plasma cell proliferation and monoclonal plasmacytic

infiltration (10). EMPs may coexist with MM, presenting as

the main symptom, developing during the course of MM, or

occasionally occurring as isolated tumors (11,12). Intracra-

nial extramedullary plasmacytomas account for 4% of all

primary plasma cell tumors (3). In patients with a diagnosis

of MM, the presence of intracranial EMPs, as a result of the

metastatic spread of MM, is rare, occurring in 1% of all the

reported cases (13,14). To the best of our knowledge, <30 cases of

renal plasmacytoma have been reported in the literature

previously (15). In the cases of renal EMPs, the tumor mass

is mostly confined to this anatomical area, and <10% involve

other organs besides the kidney (16,17). Thus, to the best of

our knowledge, the initial presentation of an EMP displaying

intracranial and renal infiltration simultaneously, such as in

the present case, has not been previously described.

The diagnosis of EMP is more complicated than that of

MM, and requires radiological, hematological, biochemical

and histological examinations. Due to the absence of typical

clinical symptoms and evidence from specific laboratory tests,
a diagnosis of EMP may be delayed or missed, with potentially

serious consequences for the patient. In the present case, EMP

was diagnosed based on the clinical symptoms of the patient,
alongside the imaging findings and the results of the serum

Ig electrophoresis and the histopathological analyses of tissue

biopsy and bone marrow aspirate.

To date, there are no specific guidelines for the treatment

of EMP presenting with MM. The current treatment options

for EMP include surgery, chemotherapy and radiotherapy,
either alone or in combination (3,15). If the tumor is located

in an area with restricted surgical access, a complete resection

with fractionated radiotherapy at the tumor site may be a good

option for intracranial plasmacytomas. However, a number

of case reports have highlighted the use of systemic chemo-
therapy and radiotherapy as the most important part of the

treatment (18,19). Recent studies on the fundamental molecular

mechanisms responsible for MM cell growth and survival have

led to the introduction of novel classes of pharmacological

agents, including immunomodulatory drugs and proteasome

inhibitors (20). In the present case, combined chemotherapy

was selected as the treatment for EMP, due to the patient’s age

and body condition. In this context, chemotherapy may be an attrac-
tive option for certain cases, for example when the treatment is

aimed at improving the quality of life of patients rather than at

increasing the survival rate, particularly in elderly patients.

In conclusion, the simultaneous presentation of EMP in the

kidney and head is rare. Thus, the present case report may aid

in the diagnosis and treatment of future cases of EMPs.

References


